Fiche publication
Date publication
juin 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BILGER Karin
,
Dr CAILLOT Denis
,
Dr DRENOU Bernard
Tous les auteurs :
Hermet E, Cabrespine A, Guieze R, Garnier A, Tempescul A, Lenain P, Bouabdallah R, Vilque JP, Frayfer J, Bordessoule D, Sibon D, Janvier M, Caillot D, Biron P, Legros L, Choufi B, Drenou B, Gorin NC, Bilger K, Tamburini J, Soussain C, Brechignac S, Bay JO
Lien Pubmed
Résumé
INTRODUCTION: Limited data is available on the feasibility of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) in elderly patients over 70years of age with non-Hodgkin's lymphoma (NHL). MATERIALS AND METHODS: In the setting of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) group, we retrospectively analyzed 81 consecutive patients with NHL over 70years of age who received AHSCT. RESULTS: The median age at AHSCT was 72.3years [70-80]. Patients' were diagnosed with diffuse large B-cell lymphoma (n=40), follicular lymphoma (n=16), mantle cell lymphoma (n=15), T-cell lymphoma (n=5), and other (n=5). Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) was 0 in 73% of patients. Main conditionings were BEAM (Carmustine-Etoposide-Cytarabine-Melphalan, n=61) and melphalan alone (n=14). Median delays to reach 0.5x109/L neutrophils and 20x109/L platelets were of 12 [9-76] days and 12 [0-143] days, respectively. One hundred day and one year cumulative incidence of NRM was 5.4% and 8.5%, respectively. The main cause of death remains relapse. CONCLUSION: In conclusion, this study revealed that AHSCT seemed to be acceptable in patients over 70years of age with NHL. Patient age is not a limiting factor if clinical condition is adequate.
Référence
J Geriatr Oncol. 2015 Jun 23. pii: S1879-4068(15)00054-5
